The study was conducted to examine the influence of two methods of modeling of ischemic heart disease on the amount of ischemic fibers in the myocardium parameters, characterizing the cardiovascular system, the coagulation properties of blood, and its electrolyte composition. It was shown that at modeling of IHD by introducing doxorubicin, several functional changes occurred, but the nature of the changes of the studied parameters evidenced a predominantly cardiotoxic effect of doxorubicin, which did not lead to the morphological picture characteristic of IHD. At modeling of ischemic heart disease by co-administering adrenaline and hydrocortisone, morphofunctional disorders were manifested in significant pathological changes in the myocardium of rats, and this method can be used as a model to identify the therapeutic efficacy of potential drugs aimed at preventing and treating the ischemic heart disease.
Tunstall-Pedoe, H. MONICA, monograph and multimedia sourcebook: world's largest study of heart disease, stroke, risk factors, and population trends 1979-2002. World Health Organization, 2003 – 244 p.
Dahmardeh, H. & Sedaghat, M. (2017). “Epi-demiological investigation of cardiovascular diseases in Khatamol Anbia Hospital in Zahedan city in 2016”, Pharmacophore, 8(6),60-63.
Marzangi A, Ahangarzadeh Rezaei S*, Ghareagaji Asl R. (2018). “Health literacy and its relation to quality of life in people with heart disease” . International Journal of Pharmaceutical and Phytopharmacological Research, 8(3), pp.25-32.
Volpe, M., Battistoni, A., Gallo, G., Rubattu, S., Tocci, G., & Writing Committee. (2018). Executive Summary of the 2018 Joint Consensus Document on Cardiovascular Disease Prevention in Italy. High Blood Pressure & Cardiovascular Prevention, 25(3), 327-341.
Liu-qiang, Lv. Yang-zhang,T. Shi-qiang, W. Yi-min, X. Ling, G. and Xun-min, Ch. Research on the Clinical Phenotype of Coronary Heart Dis-ease with Retinol Binding Protein 4, Lipopro-tein-related Phospholipase A2, and the Severi-ty of Coronary Artery Lesion. International Journal of Pharmaceutical Research & Allied Sciences, 2017, 6(1):107-112.
Al Badarin, F., Aljizeeri, A., Almasoudi, F., & Al-Mallah, M. H. (2017). Assessment of myocardial blood flow and coronary flow reserve with positron emission tomography in ischemic heart disease: Current state and future directions. Heart failure reviews, 22(4), 441-453.
Alatorre, C. I., Hoogwerf, B. J., Deeg, M. A., Nelson, D. R., Hunter, T. M., Ng, W. T., & Rekhter, M. D. (2018). Factors associated with stroke, myocardial infarction, ischemic heart disease, unstable angina, or mortality in patients from real world clinical practice with newly-diagnosed type 2 diabetes and early glycemic control. Current medical research and opinion, 34(2), 337-343.
Kuzmiak-Glancy, S., Covian, R., Femnou, A. N., Glancy, B., Jaimes III, R., Wengrowski, A. M., ... & Kay, M. W. (2017). Cardiac performance is limited by oxygen delivery to the mitochondria in the crystalloid-perfused working heart. American Journal of Physiology-Heart and Circulatory Physiology, 314(4), pp.704-715.
Omland, T., & White, H. D. (2017). State of the art: blood biomarkers for risk stratification in patients with stable ischemic heart disease. Clinical chemistry, 63(1), 165-176.
Zipes, D. P., Libby, P., Bonow, R. O., Mann, D. L., & Tomaselli, G. F. (2018). Braunwald's Heart Disease E-Book: A Textbook of Cardiovascular Medicine. Elsevier Health Sciences.
Sommer, C. J. (2017). Ischemic stroke: experimental models and reality. Acta neuropathologica, 133(2), 245-261.
Carvalho, F. S. Doxorubicin‐induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy/ F. S. Carvalho, A. Burgeiro, R.Garcia, A. J. Moreno, R. A. Carvalho, P. J. Oliveira //. Medicinal research reviews, 2017-34(1),P.106-135.
Chatterjee, K. Doxorubicin cardiomyopathy / K. Chatterjee, J. Zhang, N. Honbo, J. S. Karliner //Cardiology. – 2010.V. 115(2). Р.155-162.
Gaman, D.V. Features of morfofunktsionalny ultrastructure of heart at experimental ischemia of a myocardium // D.V. Gaman, M.I. Konopenko, T.Yu. Tyubka is Uke. Biopharmaceutical Journal. 2011; 10 (5): Pages 16-20.